Literature DB >> 9461007

Clinical course and prognostic factors following bone recurrence from breast cancer.

R E Coleman1, P Smith, R D Rubens.   

Abstract

Three hundred and sixty-seven women presenting to the Breast Unit at Guy's Hospital between 1975 and 1990 whose first distant metastasis was in the skeleton were identified and the influence of a number of patient and tumour characteristics on the development and subsequent prognosis of bone metastases was assessed. One hundred and thirty-nine women had disease that remained clinically confined to the skeleton. They were more likely to be older, with lobular carcinoma and to have presented initially with little or no axillary lymph node involvement. The 228 women who subsequently developed disease at extra-osseus sites were more likely to have poorly differentiated ductal tumours and heavy lymph node involvement at primary diagnosis. On multivariate analysis, the clinical and pathological factors of greatest prognostic importance for survival after the development of bone metastases were histological grade (P = < 0.0001), oestrogen receptor status (P = < 0.0001), bone disease at initial presentation (P = < 0.0001), disease-free interval (P = 0.002) and age (P = 0.006).

Entities:  

Mesh:

Year:  1998        PMID: 9461007      PMCID: PMC2151240          DOI: 10.1038/bjc.1998.52

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Parathyroid hormone related protein and skeletal morbidity in breast cancer.

Authors:  N J Bundred; R A Walker; W A Ratcliffe; J Warwick; J M Morrison; J G Ratcliffe
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

2.  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

Authors:  P F Conte; J Latreille; L Mauriac; F Calabresi; R Santos; D Campos; J Bonneterre; G Francini; J M Ford
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

Review 3.  Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors.

Authors:  H I Scher; A Yagoda
Journal:  Am J Med       Date:  1987-02-23       Impact factor: 4.965

4.  Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group.

Authors:  P G Koenders; L V Beex; R Langens; P W Kloppenborg; A G Smals; T J Benraad
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

5.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

Authors:  A H Paterson; T J Powles; J A Kanis; E McCloskey; J Hanson; S Ashley
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

6.  Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization.

Authors:  S J Vargas; M T Gillespie; G J Powell; J Southby; J A Danks; J M Moseley; T J Martin
Journal:  J Bone Miner Res       Date:  1992-08       Impact factor: 6.741

7.  High-dose intravenous pamidronate for metastatic bone pain.

Authors:  O P Purohit; C Anthony; C R Radstone; J Owen; R E Coleman
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

8.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

10.  The clinical course of bone metastases from breast cancer.

Authors:  R E Coleman; R D Rubens
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

View more
  75 in total

1.  Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.

Authors:  Naoki Niikura; Jun Liu; Naoki Hayashi; Shana L Palla; Yutaka Tokuda; Gabriel N Hortobagyi; Naoto T Ueno; Richard L Theriault
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

2.  Tumor dormancy in bone.

Authors:  Vera Mayhew; Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-29

3.  Radionuclide Therapy of Bone Metastases.

Authors:  Manfred Fischer; Willm U Kampen
Journal:  Breast Care (Basel)       Date:  2012-04-24       Impact factor: 2.860

4.  A prospective study of bone tumor response assessment in metastatic breast cancer.

Authors:  Naoki Hayashi; Colleen M Costelloe; Tsuyoshi Hamaoka; Caimiao Wei; Naoki Niikura; Richard L Theriault; Gabriel N Hortobagyi; John E Madewell; Naoto T Ueno
Journal:  Clin Breast Cancer       Date:  2012-10-24       Impact factor: 3.225

5.  Quality of life (QOL) and symptom burden (SB) in patients with breast cancer.

Authors:  Julia Hamer; Rachel McDonald; Liying Zhang; Sunil Verma; Angela Leahey; Christine Ecclestone; Gillian Bedard; Natalie Pulenzas; Anchal Bhatia; Ronald Chow; Carlo DeAngelis; Janet Ellis; Eileen Rakovitch; Justin Lee; Edward Chow
Journal:  Support Care Cancer       Date:  2016-09-30       Impact factor: 3.603

Review 6.  Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates.

Authors:  Nicola Lucio Liberato; Monia Marchetti; Giovanni Barosi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists.

Authors:  Sunil Verma; Danielle Kerr-Cresswell; George Dranitsaris; Flay Charbonneau; Maureen Trudeau; Geetha Yogendran; Anne-Marie Cesta; Mark Clemons
Journal:  Support Care Cancer       Date:  2004-08-21       Impact factor: 3.603

Review 8.  Mechanisms of bone metastases of breast cancer.

Authors:  Larry J Suva; Robert J Griffin; Issam Makhoul
Journal:  Endocr Relat Cancer       Date:  2009-05-14       Impact factor: 5.678

9.  Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease.

Authors:  Daniel M Sciubba; Ziya L Gokaslan; Ian Suk; Dima Suki; Marcos V C Maldaun; Ian E McCutcheon; Remi Nader; Richard Theriault; Laurence D Rhines; Joseph A Shehadi
Journal:  Eur Spine J       Date:  2007-05-08       Impact factor: 3.134

10.  Importance of the development time of isolated bone metastasis in breast cancer.

Authors:  Sevim Turanli
Journal:  Langenbecks Arch Surg       Date:  2009-11-17       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.